You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

58 search results for: guidelines

GOLD 2024 Diagnosis and Assessment of COPD
videoanimation

GOLD 2024 Diagnosis and Assessment of COPD

Pulmonology
This short video presentation outlines the diagnosis and assessment of COPD according to the 2024 GOLD report, focusing on clinical features and assessment goals.
View more
COPD and Asthma: What's the Difference and Is There a Link?
interactivity

COPD and Asthma: What's the Difference and Is There a Link?

Pulmonology
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.
View more
Emerging Therapeutic Landscape and Implications for Patient Management in CSU
expert video

Emerging Therapeutic Landscape and Implications for Patient Management in CSU

Dermatology
A review of disease burden and treatment needs in CSU, and how current and emerging therapies can impact patient management.
View more
Updates in PN and CSU: Emerging Therapeutic Landscapes and Implications for Patient Management
expert video

Updates in PN and CSU: Emerging Therapeutic Landscapes and Implications for Patient Management

Dermatology
A review of disease burden and treatment needs in PN and CSU, and how current and emerging therapies can impact patient management in these respective diseases.
View more
Emerging Therapeutic Landscape and Implications for Patient Management in PN​
expert video

Emerging Therapeutic Landscape and Implications for Patient Management in PN​

Dermatology
A review of disease burden and treatment needs in PN, and how current and emerging therapies can impact patient management.
View more
From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

Rhinology
Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP.
View more
Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe CRSwNP
expert video

Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe CRSwNP

Rhinology
Prof. Peter Hellings presents the comparative efficacy of biologics for patients with uncontrolled and/or severe CRSwNP.
View more
GINA Asthma Decision Tree
videoanimation

GINA Asthma Decision Tree

Pulmonology
Walk through the GINA decision tree for severe asthma
View more
On-Treatment Asthma Remission: Moving Beyond Control
interactivity

On-Treatment Asthma Remission: Moving Beyond Control

Pulmonology
Learn about the proposed framework for clinical remission in patients with asthma
View more
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
expert video

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

Rhinology
Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.
View more
Clinical Remission as a Goal in Asthma Clinical Practice
expert video

Clinical Remission as a Goal in Asthma Clinical Practice

Pulmonology
Profs. Alberto Papi and Ian Pavord discuss clinical remission as a goal in asthma clinical practice beyond symptom control
View more
Adult Asthma Interactive Patient Cases
interactivity

Adult Asthma Interactive Patient Cases

Pulmonology
Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region